7,554 press releases indexed under healthcare.
Natura Pro Skin Tag Remover ingredients, bloodroot, Zincum Muriaticum, 2026 pricing, reviews and complaints, refund terms, customer support, FDA context, and key buyer considerations are examined for consumers researching the at-home formula.
As men's wellness remains a high-interest category in 2026, this Vapofil review explores the brand-stated seven-ingredient formula, exact label amounts, pricing, and how the supplement is positioned for circulation, hormonal balance, prostate health, and everyday vitality support-along with the key details buyers should verify before ordering.
If batch-level lab access, product variety, transparent pricing, and traceability are high on the buyer checklist, this Super Speciosa review examines why the brand may warrant a closer look in 2026-plus the product, policy, FDA, DEA, and local-law details consumers should verify before ordering.
As GLP-1 users explore what may come next in their body-composition journey, this NEOLISE Sculpt review examines the brand's tesamorelin positioning, who the program is marketed toward, pricing, provider evaluation, clinical evidence, and the practical questions buyers are weighing before deciding whether it fits their goals.
As more consumers explore provider-guided longevity programs in 2026, this NEOLISE Longevity review examines the brand's CJC-1295 + ipamorelin protocol, current pricing, prescription process, FDA status, and the factors buyers may want to compare before deciding whether the program fits their long-term wellness routine.
CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase...
For buyers drawn to a simpler, no-boil snoring-support option, this Snorelio review examines the brand-stated jaw-positioning design, current pricing, return terms, company details, and unresolved FDA and review-verification questions that could shape whether it fits their nighttime routine.
As more consumers explore provider-guided peptide options for recovery support in 2026, this NEOLISE Recovery review examines the brand-stated BPC-157/TB-500 protocol, current pricing, telehealth process, FDA compounding status, and the details buyers are comparing before deciding whether to request a clinical evaluation.
NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 9, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..
As interest in skin and hair wellness options grows in 2026, this NEOLISE Renewal review explores the brand-stated GHK-Cu, BPC-157, TB-500 and KPV formulation, how the prescription pathway is positioned for adults researching visible skin aging and hair thinning, what buyers receive with each plan, and the pricing, provider, pharmacy and FDA-compounding questions worth checking before enrolling.
WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV). The data, presented in a poster session at the 2026 Society of Hematologic Oncology (SOHO) annual meeting in Houston, TX, demonstrated that treatment with DISC-3405 increased hepcidin and lowered serum iron, translating to reduction in phlebotomy, controlled hematocrit, and improved symptom burden in patients with PV. These data will be featured in an oral presentation at the SOHO conference tomorr